TABLE 1.
Case 1 | Case 2 | Case 3 | Case 4 | Case 5 | Case 6 | Case 7 | Case 8 | Case 9 | |
---|---|---|---|---|---|---|---|---|---|
Age (years) | 53 | 57 | 45 | 64 | 31 | 17 | 30 | 68 | 50 |
Sex | Female | Male | Male | Male | Male | Male | Female | Female | Male |
Hematological disease | |||||||||
Diagnosis | AA | AML‐M5 | AML‐M5 | AML‐M5 | Ph+ B‐ALL | Ph+ B‐ALL | Ph‐like ALL | DLBCL | MM |
Remission | No | Yes | Yes | No | Yes | Yes | No | Yes | Yes |
Agranulocytosis | Yes | No | No | Yes | No | No | Yes | No | No |
Time of last treatment | Within 1 mo | Within 1 mo | Within 1 mo | 4 d ago | Duration | Within 1 mo | Duration | Within 1 mo | Within 3 mo |
Last treatment regimen | CsA | Dec, HA | Dec, IA | Dec | Dasatinib | Dasatinib, VP | Sorafenib Venetoclax | R‐CHOP | BCMA‐CAR T cell |
SARS‐CoV‐2 | |||||||||
Associated transmission | Community | Hospital | Hospital | Hospital | Hospital | Hospital | Hospital | Community | Hospital |
Clinical manifestation | |||||||||
Fever | Yes | Yes | Yes | Yes | No | No | Yes | No | Yes |
Fatigue | Yes | Yes | No | Yes | No | No | Yes | No | No |
Dry cough | Yes | Yes | Yes | Yes | Yes | No | Yes | Yes | Yes |
Expectoration | No | Yes | Yes | Yes | No | No | Yes | No | Yes |
Hemoptysis | Yes | No | Yes | No | No | No | No | No | No |
Dyspnea | Yes | No | Yes | No | No | No | No | Yes | Yes |
Diarrhea | No | No | No | No | Yes | No | Yes | No | No |
Nausea and vomiting | No | No | No | No | No | No | Yes | No | No |
Clinical classification | Moderate | Moderate | Moderate | Moderate | Moderate | Moderate | Moderate | Moderate | Critically |
Nucleic acid and Ab testing | |||||||||
Throat swabs | Negative | Positive | Negative | Positive | Negative | Negative | Positive | Positive | Positive |
Plasma (copies/mL) | ND | ND | 1384 | ND | 250 | 116 | ND | ND | 5044 |
Ab | Positive | Positive | Negative | ND | Negative | Negative | ND | Negative | Negative |
Therapy | |||||||||
Antiviral | Arbidol | Arbidol Lopinavir Ritonavir | Arbidol | Arbidol | Arbidol Lopinavir Ritonavir | Arbidol Lopinavir Ritonavir | Arbidol Lopinavir Ritonavir | Arbidol | Arbidol Lopinavir Ritonavir |
Antibiotics | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes |
Antifungal | Yes | Yes | Yes | Yes | No | Yes | Yes | No | Yes |
Immunoglobulin | Yes | Yes | No | Yes | No | No | Yes | No | Yes |
Corticosteroids | No | No | No | No | Yes | Yes | No | No | Yes |
Oxygen therapy | IMV | No | Nasal catheter | NMV | Nasal catheter |
Nasal catheter |
Nasal catheter |
Nasal catheter | NMV |
Clinical outcomes | |||||||||
Outcome | Death | Stay in hospital | Discharged from hospital | Death | Discharged from hospital |
Discharged from hospital |
Death | Discharged from hospital | Death |
Cause of death | Septicopyemia | NA | NA | Septic shock | NA | NA | Intracranial invasion | NA | Respiratory failure |
Abbreviations: Ab, antibody; AA, aplastic anemia; AML‐M5, acute monocytic leukemia; B‐ALL, acute B lymphoblastic leukemia; BCMA‐CAR, B‐cell maturation antigen chimeric antigen receptor; CsA, cyclosporine A; Dec, decitabine; DLBCL, diffuse large B‐cell lymphoma; HA, homoharringtonine, cytarabine; IA, idarubicin, cytarabine; IMV, invasive mechanical ventilation; MM, multiple myeloma; NA, not available; ND, not done; NMV, noninvasive mechanical ventilation; R‐CHOP, rituximab, cyclophosphamide, epirubicin, vindesine, prednisolone; SARS‐CoV‐2, severe acute respiratory syndrome coronavirus 2; VP, vindesine, prednisolone.